ストックスクリーナーアプリを入手
48.24
3.56%
1.66
アフターアワーズ：
48.24
Bridgebio Pharma Inc (BBIO) 最新ニュース
BBOT Debuts as a Publicly Traded Company Focused on - GlobeNewswire
BridgeBio’s oncology spinout sticks with SPAC to land on Nasdaq - Endpoints News
BridgeBio Pharma Inc. Stock Approaches Key Moving AverageAI Driven Stock Trend Forecast Shows Momentum Shift - beatles.ru
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - 富途牛牛
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - simplywall.st
Scotiabank Keeps Their Buy Rating on BridgeBio Pharma (BBIO) - The Globe and Mail
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $57 to $62 - 富途牛牛
BridgeBio Pharma Shares Plunge 8.94% as $620M Trading Volume Surges 126.94% to Top 500-Stock Volume Rankings Despite $110M Revenue Growth and 3,751 Prescriptions for Attruby - AInvest
BridgeBio Pharma 2025 Q2 Earnings Deepened Losses Amid Record Revenue Growth - AInvest
BridgeBio Pharma stock hits 52-week high at 48.74 USD By Investing.com - Investing.com Australia
BridgeBio Earnings: Attruby Ramp Supports Long-Term Growth Outlook - Morningstar
BridgeBio Pharma stock rating reiterated at Buy by TD Cowen on strong Attruby sales - Investing.com Canada
As competition heats up, BridgeBio's Attruby sales underwhelm Wall Street despite growth - Endpoints News
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive
BridgeBio Becomes The Victim Of Its Own Success As Attruby Gathers Steam - insights.citeline.com
Bridgebio Pharma shares fall 8.86% in premarket after Q2 earnings miss and Trump's tariff announcement. - AInvest
Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics - The Manila Times
BridgeBio Pharma stock price target raised to $61 by Oppenheimer - Investing.com Nigeria
Helix Acquisition Corp. II Retains Over 60% of Trust Account After Redemptions in BridgeBio Oncology Therapeutics Deal, Securing $382 Million in Gross Proceeds. - AInvest
BridgeBio Oncology Lands Massive $382M SPAC Deal as Top Investors Back Cancer Drug Pipeline - Stock Titan
BridgeBio Pharma Beat Estimates With Strong Q2 Revenue Growth - Finimize
BridgeBio Pharma Plunges 12.21% Amid Factory Orders Drop - AInvest
BridgeBio Pharma: Q2 Earnings Snapshot - New Haven Register
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... - Yahoo Finance
BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... By GuruFocus - Investing.com Canada
BridgeBio Pharma Reports Strong Q2 2025 Results - TipRanks
Transcript : BridgeBio Pharma, Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Earnings call transcript: BridgeBio Pharma sees revenue surge in Q2 2025 By Investing.com - Investing.com South Africa
Earnings call transcript: BridgeBio Pharma sees revenue surge in Q2 2025 - Investing.com
BridgeBio Pharma earnings missed by $0.20, revenue topped estimates - Investing.com South Africa
BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
BridgeBio Pharma, Inc. SEC 10-Q Report - TradingView
Why BridgeBio Pharma's Q2 Revenue Beat Signals a Catalyst for Outperformance - AInvest
BridgeBio Earnings: Attruby Sales Surge to $71M with Major Phase 3 Results Coming Fall 2025 - Stock Titan
BridgeBio Pharma stock hits 52-week high at 48.74 USD - Investing.com
BridgeBio Pharma Inc (BBIO) Q2 2025: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
What makes BridgeBio Pharma Inc. stock price move sharplySkyrocketing returns - Jammu Links News
Is BridgeBio Pharma Inc. a growth stock or a value stockMaximize your returns with smart trade entries - Jammu Links News
How strong is BridgeBio Pharma Inc. company’s balance sheetConsistently high returns - Jammu Links News
Is it the right time to buy BridgeBio Pharma Inc. stockFree Stock Movement Tracking - Jammu Links News
How does BridgeBio Pharma Inc. generate profit in a changing economyBeginner Investor Watchlist For 2025 - Jammu Links News
Can volume confirm reversal in BridgeBio Pharma Inc.AI Forecast for Trending Stocks Indicates Upside - metal.it
Cantor Fitzgerald Remains a Buy on BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma Inc. stock volume spike explainedPotential Breakout Stock List Published This Week - metal.it
Raymond James assumes coverage on BridgeBio stock with Outperform rating - Investing.com Canada
BridgeBio Pharma Inc. Breaks Losing Streak — Is the Trend ReversingEarly Entry Tips With Low Risk Zone Shared - metal.it
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Cantor Fitzgerald maintains BridgeBio stock rating, sees $3B+ potential By Investing.com - Investing.com Canada
Truist Sees Upside in BridgeBio Pharma’s (BBIO) ATTR-CM Strategy - MSN
BridgeBio Pharma Inc. Hits Oversold Level on RSI IndicatorEntry Alert Based on Volume Spikes Detected - metal.it
1.02%
3.70%
大文字化:
|
ボリューム (24 時間):